FDA Action Alert: Mesoblast, Sage/Biogen and Galera

The FDA has three decision deadlines over the next two weeks, including action dates for therapeutics targeting depression, graft-versus-host disease and a radiotherapy-induced side effect in patients with head and neck cancer.